Notice of Proposed Sale · 144
Mineralys Therapeutics, Inc.
MLYSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Mineralys Therapeutics, Inc.
- Issuer CIK
- 0001933414
- SEC file number
- 001-41614
- Phone
- (888) 378-6240
- Person for whose account securities are to be sold
- Congleton Jon
- Relationships to issuer
- Officer · Director
- Street
- 150 N. RADNOR CHESTER ROAD
- Street (continued)
- SUITE F200
- City
- RADNOR
- State / country code
- PA
- Postal code
- 19087
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 75,000 | 1,909,661.61 | 88,406,885 | 09/30/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 225 Liberty St
- Street (continued)
- 37th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10281
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 01/10/2025 | Vesting of Restricted Stock Unit Awards | Mineralys Therapeutics, Inc. | 3,194 | N | 01/10/2025 | Granted as part of issuer equity compensation plan |
| Common Stock | 04/10/2025 | Vesting of Restricted Stock Unit Awards | Mineralys Therapeutics, Inc. | 20,635 | N | 04/10/2025 | Granted as part of issuer equity compensation plan |
| Common Stock | 07/10/2025 | Vesting of Restricted Stock Unit Awards | Mineralys Therapeutics, Inc. | 20,070 | N | 07/10/2025 | Granted as part of issuer equity compensation plan |
| Common Stock | 10/10/2025 | Vesting of Restricted Stock Unit Awards | Mineralys Therapeutics, Inc. | 20,854 | N | 10/10/2025 | Granted as part of issuer equity compensation plan |
| Common Stock | 01/10/2026 | Vesting of Restricted Stock Unit Awards | Mineralys Therapeutics, Inc. | 10,247 | N | 01/10/2026 | Granted as part of issuer equity compensation plan |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Jon Congleton | Common Stock | 06/30/2026 | 75,000 | 1,960,601.58 |
| Jon Congleton | Common Stock | 07/13/2026 | 10,700 | 291,441.17 |
Seller — prior-sale row 1, entry 1
- Name
- Jon Congleton
- Street
- 150 N. RADNOR CHESTER RD
- Street (continued)
- SUITE F200
- City
- RADNOR
- State / country code
- PA
- Postal code
- 19087
Seller — prior-sale row 2, entry 1
- Name
- Jon Congleton
- Street
- 150 N. RADNOR CHESTER RD
- Street (continued)
- SUITE F200
- City
- RADNOR
- State / country code
- PA
- Postal code
- 19087
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 09/30/2026
- Signed
- Jon Congleton
- Plan adoption dates
- 12/23/2025
Company context
Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.